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Abstract
Genetic investigations of X-linked intellectual disabilities have implicated the ARX (Aristaless-related homeobox) gene in a
wide spectrum of disorders extending from phenotypes characterised by severe neuronal migration defects such as
lissencephaly, to mild or moderate forms of mental retardation without apparent brain abnormalities but with associated
features of dystonia and epilepsy. Analysis of Arx spatio-temporal localisation profile in mouse revealed expression in
telencephalic structures, mainly restricted to populations of GABAergic neurons at all stages of development. Furthermore,
studies of the effects of ARX loss of function in humans and animal models revealed varying defects, suggesting multiple
roles of this gene during brain development. However, to date, little is known about how ARX functions as a transcription
factor and the nature of its targets. To better understand its role, we combined chromatin immunoprecipitation and mRNA
expression with microarray analysis and identified a total of 1006 gene promoters bound by Arx in transfected
neuroblastoma (N2a) cells and in mouse embryonic brain. Approximately 24% of Arx-bound genes were found to show
expression changes following Arx overexpression or knock-down. Several of the Arx target genes we identified are known to
be important for a variety of functions in brain development and some of them suggest new functions for Arx. Overall,
these results identified multiple new candidate targets for Arx and should help to better understand the pathophysiological
mechanisms of intellectual disability and epilepsy associated with ARX mutations.
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Introduction
Intellectual disability (ID) is usually defined as a heterogeneous
group of disorders resulting from a variety of acquired and genetic
causes, and is thought to affect approximately 1% of the
population across the world [1]. The observation that ID is
preferentially expressed in males has led to focus on genes located
on the X chromosome. To date, more than 90 associated genes
have been identified [2]. One of the most frequently mutated
genes is the Aristaless-related homeobox (ARX) gene (Entrez Gene
170302) located on Xp22.13. It was first identified in 2002 as
involved in non-syndromic X-linked mental retardation (OMIM
300382 and 300419) [3] and West syndrome (OMIM 308350)
[4,5]. Since then, several other mutations have been described and
implicated ARX in a wide spectrum of disorders extending from
phenotypes with severe neuronal migration defects such as X-
linked lissencephaly with abnormal genitalia (XLAG), to milder
forms of mental retardation without apparent brain abnormalities
but with associated features of dystonia and epilepsy [3–10].
Although Arx is expressed in several structures including the
brain, pancreas, developing testes, heart, skeletal muscle and liver
[3,6,11–13], the most striking consequences of Arx loss of function
concern the brain and testis in both mouse and human. In the
developing and adult brain, Arx is strongly expressed in
telencephalic structures, particularly in populations of GABA-
containing neurons [15–17]. Recent studies of the effects of Arx
loss of function revealed that this gene contributes to almost all
fundamental processes of brain development: patterning, neuronal
proliferation and migration, neuronal maturation and differenti-
ation as well as axonal outgrowth [6,14,17,18].
Arx encodes a transcription factor which belongs to one of the
three largest classes of homeoproteins, the paired (Prd) class.
Genes from this family are characterised by a 60-amino acid
homeodomain responsible for DNA-binding. In addition, they
often contain other motifs that can contribute to DNA and/or co-
factor binding specificity. For example, the highly conserved
octapeptide domain located in the N-terminal part of Arx, as well
as another C-terminal region including the fourth polyalanine
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related domain, located at the C-terminus, has transcriptional
activator activity [19,20]. A few co-factors of Arx have been
identified: the Groucho/transducin-like enhancer of split (TLE)
family of co-repressors interacts with Arx octapeptide, whereas
repression by the second domain occurs through the interaction
with C-terminal binding proteins (CtBPs) [20]. In addition, Arx
has four polyalanine tracts. The two ones located in the N-
terminal part of Arx seem particularly important for the function
of the protein as several expansions have been identified in
patients. For this type of mutations, it has recently been suggested
that the level of transcriptional repression activity may depend on
the length of the alanine expansion [19]. Changes in the
transcriptional activity of Arx may thus have subtle effects on
neuronal function and contribute to the pathogenesis of ARX-
related disorders, in particular intellectual deficiency and epilepsy.
Although two gene expression profile analyses comparing E14.5
wild-type and Arx mutant ventral telencephalic tissues have
recently been published in mouse, very few targets for this
transcription factor have been described and only three (Lmo1,
Ebf3 and Shox2) have been found to be direct [21,22]. Here, using
chromatin immunoprecipitation in Arx-transfected neuroblastoma
cells (N2a) or E15.5 mouse embryonic brain, followed by
hybridization to mouse promoter arrays (ChIP-chip) [23], we
identified new direct targets of Arx. We found a total of 1006 Arx-
bound genes. A significant proportion of these promoters were
enriched for a sequence very similar to a motif previously
identified as Arx-binding motif. Both fixation and regulation of
subsets of these targets have then been confirmed by ChIP-PCR
and by the analysis of transcriptomic experiments performed from
either Arx-overexpressing N2a cells or Arx knock-out mice.
Results
Assessment of the specificity of the ChIP protocol
To better understand the role of Arx and the effect of its
mutations on brain development, we used chromatin immuno-
precipitation on promoter arrays (ChIP-chip) to identify direct
targets of this transcription factor. As Arx is not endogenously
expressed in any known neuronal cell line, we decided to use Arx-
transfected mouse neuroblastoma (N2a) cells. This cell line has
recently been used to validate three direct targets of Arx (Lmo1,
Ebf3 and Shox2) [21]. We first tested the ability of two different
polyclonal Arx antibodies (anti-Arx-HD directed against the
homeodomain region of Arx and produced by Poirier et al. [15]
and Arx C-14 from Santa Cruz directed against the C-terminal
part of the protein) to work in protein immunoprecipitation. Both
antibodies could immunoprecipitate the transfected Arx protein,
however the antibody from Santa Cruz seemed a bit more efficient
than anti-Arx-HD (data not shown and Figure 1A). To test the
ability of these antibodies to work in chromatin immunoprecip-
itation, we took advantage of the previous identification of three
direct targets of Arx [21]. N2a cells transfected with Arx were first
treated with formaldehyde to preserve interactions between Arx
and its target DNA. Following cell lysis, genomic DNA was
sheared into fragments of 300–600 bp and precipitated using i)
one of the two polyclonal Arx antibodies, ii) an antibody directed
against DNA Polymerase II which is known to bind the Gapdh
gene, iii) without any antibody. Then, the presence of Lmo1, Ebf3
and Shox2 in each immunoprecipitate was assessed by quantitative
PCR (qPCR) (Figure 1B). The results showed that Arx C-14
antibody yielded successful enrichment of the 3 specific targets
which, on the opposite, were not present in the anti-PolII
immunoprecipitates (Figure 1B). Similar results were obtained
with anti-Arx-HD although this antibody seemed slightly less
specific (data not shown). We thus decided to use the commercial
antibody in most of the following experiments. We then amplified,
labelled and cohybridized Arx-immunoprecipitated DNA and
total DNA input onto Agilent mouse promoter arrays.
Identification of an Arx-binding motif in ChIP-positive
sequences obtained from Arx-transfected N2a cells
The mouse promoter microarrays from Agilent Technologies
(G4490A) consist of two arrays with approximately 244 000 60-
mer oligonucleotide probes spaced every 100–300 bp across
regions of interest. They cover 25.5 kb upstream to +2.5 kb
downstream of the transcriptional start sites of approximately
17,000 of the best-defined mouse genes. These arrays have
previously been used to identify binding sites of other important
transcription factors such as Pax6 [24]. Three independent ChIP-
chip experiments were performed from N2a cells transfected with
Arx. As previously described (Figure 1B), the enrichment of Lmo1,
Ebf3 and Shox2 was checked in each replicate before immunopre-
cipitated DNA was applied to the microarrays. These experiments
identified 927 genes consistently enriched in Arx-immunoprecip-
itated material (geometrical mean of the P-values of the 3
experiments #10
24 with a P-value,10
23 in at least 2 experi-
ments) (Table S1) (Figure 2A–B).
To investigate whether target genes contain a consensus motif
that could correspond to Arx-binding motif, we took the 500 most
enriched genes based on P-values (Table S1) and used an unbiased
approach with the MDModule of the MotifRegressor program
[25] to identify sequence motifs enriched within 450 bp of the
center of the corresponding positive probes. This approach
detected several motifs in a significant number of Arx-immuno-
precipitated probes. Similar motifs were then gathered using the
MotifsComparator program [26] to lead to a consensus sequence,
which appeared to be similar to the one defined by Berger et al.
[27] as Arx-binding motif (Figure 2C). These authors identified
this motif by using protein-binding microarrays to determine the in
vitro DNA-binding preferences of several mouse homeodomains to
all possible 8-nucleotide sequences [27]. In our experiments, the
Arx-immunoprecipitated promoters were unambiguously enriched
for this motif by comparison to control (P-value not significant in
any replicate) promoter regions not bound by Arx (Figure 2D).
Next, we used the EMBOSS Profit algorithm to search all ChIP-
positive probes using both motifs. We found that 490 genes
(<53%) of promoter regions bound by Arx in all three
experiments contained one or several motifs with at least 75%
similarity to Arx-binding motif. This result was significantly higher
than the number of motifs obtained in a set of control (probes with
a P-value not significant in any replicate) sequences.
Identification of Arx targets from mouse embryonic
brains
To validate these results in a more physiological situation, we
decided to do similar experiments from E15.5 mouse embryonic
brains, which correspond to an important time for neuronal
migration and differentiation and which shows a high expression
of Arx. We thus performed 3 independent experiments, hybrid-
izing Arx-associated chromatin fragments to the same promoter
microarrays. In total, 369 genes were found consistently enriched
in Arx-immunoprecipitated material (geometrical mean of the P-
values of the 3 experiments #10
23 with a P-value,10
23 in at least
2 experiments) (Table S1) (Figure 3A–B). Our results revealed that
out of these 369 genes, 290 were common to those identified in
transfected N2a cells (Figure 3C).
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sequences identified in embryonic brain for both Arx-binding
motifs (Figure 2C). Surprisingly, out of 369 genes, only 74 (20%)
were found to have at least one Arx-binding site as previously
defined (Figure 3C). Among these 74 genes, 65 genes were
identified in both Arx-transfected N2a cells and mouse embryonic
brain (Figure 3C). Although we tried to identify new or
degenerated motifs in these negative sequences, we were not able
to find a motif that was significantly more present in Arx-bound
sequences by comparison to control (probes with a P-value not
significant in any replicate) sequences.
Validation of the fixation of Arx
To determine the validity of our ChIP-chip results, we
randomly selected 21 candidate Arx-bound genes displaying
representative degrees of enrichment based on P-values in the list
of 1006 genes obtained in total in ChIP experiments (Figure 3C,
Table S1). We performed quantitative QFM-PCR on Arx-
immunoprecipitated material from transfected N2a cells and
embryonic brain and compared the enrichment of these genes
with total input DNA. Binding was confirmed for 19/21 genes in
both transfected N2a cells and embryonic brain (Figure 4A). In
contrast, there was no enrichment of any of these genes in control
immunoprecipitates (anti-PolII or without any antibody) (data not
shown). Similarly, Arx did not bind to Vapb, a negative control (P-
value not significant in any experiment) (Figure 4A). These results
confirmed ChIP-chip findings for Pten, which was only identified in
N2a cells on microarrays and was also found negative in
embryonic brain by ChIP-PCR. Similarly, Jph4 which was hardly
positive in N2a cells by ChIP-chip was only confirmed in brain by
Figure 1. Assessment of the specificity of the ChIP protocol. A) Arx immunoprecipitation from N2a cells transfected with an Arx-expressing
vector or a vector alone and using the Arx C-14 antibody from Santa Cruz. Detection using the anti-Arx-HD antibody revealed a major band at
approximately 80 kD, which corresponds to the size of Arx protein. TE: total extracts, IP: immunoprecipitation, Ig: immunoglobulins. B) Enrichment of
Ebf3, Lmo1 and Shox2 promoter regions was assessed by qPCR using either Arx or PolII-immunoprecipitates or using no antibody and was compared
to the total input. Gapdh was used as a positive control with DNA Pol II. Here, we show an example of the results obtained in a ChIP experiment with
Arx C-14 antibody from Santa Cruz. The enrichment of Ebf3, Lmo1 and Shox2 was checked similarly for each replicate experiment before DNA was
applied to the microarrays.
doi:10.1371/journal.pone.0025181.g001
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to validate in both Arx-transfected N2a cells and E15.5 embryonic
brain some genes, such as Sh3tc2, Lmo3, Epha3, Cdh2, Calb2 that
were negative in ChIP experiments performed from embryonic
brains, suggesting a higher sensitivy of the quantitative ChIP-PCR
method compared to ChIP-chip, at least in embryonic brains.
Taken together, these observations confirm the specificity of our
ChIP-chip results and that Arx not only binds in vivo to some of the
290 common genes obtained in N2a cells and mouse embryonic
brain (as shown in Figure 4A for Prph, Atrx, Hist1h4h, Gabrb3,
Bhlhb5, Sema3c, Arid1a, Ppap2b, Cxcr7, Grm1, Shroom3 and Olig3), but
also to genes that were identified only in N2a transfected cells
(such as Sh3tc2, Lmo3, Epha3, Cdh2, Calb2, Crb1).
In addition, we observed that although the degree of
enrichment of candidate genes containing the TAATTA motif
(indicated by the arrows on Figure 4A) tended to be higher in Arx-
immunoprecipitates from N2a cells, there appeared to be no
correlation between the enrichment and the presence of the motif
in genes immunoprecipitated from embryonic brain (Figure 4A).
These results thus suggest that whereas overexpressed Arx seems
to be primarily recruited to target genes by direct association with
the previously defined motif, in a more physiological situation such
as in embryonic brain, Arx is either recruited by association to
other less common motifs that were not identified by MDModule
or may be recruited through interaction with other cofactors. This
hypothesis may explain why Sh3tc2, Lmo3, Epha3, Cdh2, Calb2, Crb1
genes were found to have such a high P-value in ChIP-chip
experiments from transfected N2a cells but not in mouse
embryonic brain although the interaction also exists in embryonic
brain as shown by ChIP-PCR on Figure 4A.
To provide independent validation of these results, we also
tested Lmo1, Lmo3, Sh3tc2, Cdh2 and Calb2 using a luciferase
reporter approach and measured the level of transcriptional
activity after Arx transfection into N2a cells. All five genes
displayed repressed transcriptional activity following transfection
with Arx, contrarily to the Firefly luciferase plasmid pGL4.23 alone
(Figure 4B).
Functional annotations of Arx-bound genes
To identify the cellular processes regulated by Arx, we
examined the functional annotations associated with ChIP-positive
genes, based on the Gene Ontology (GO) database [28]. Using
DAVID and Ingenuity Pathway Analysis programs, we identified
several enriched functions important for brain development and
potentially linked to neurological and/or psychological disorders
(Figure 5A). Data from transfected N2a cells revealed an
enrichment of several biological functions already known to be
associated with Arx, such as the regulation of cell cycle, gene
expression, cellular growth and proliferation (Figure 5A, left). Data
obtained from mouse embryonic brains showed, in addition, a
significant enrichment of genes that were found to be important in
mice behavior studies (Figure 5A, right). At the cellular level, Arx-
bound promoters are enriched for genes important for nuclear
transport, cell adhesion or migration, RNA processing, cell fate
Figure 2. ChIP-chip results obtained from Arx-transfected N2a cells. A) Graph representing log2 probe intensities of Arx-immunoprecipitated
DNA (IP) and input DNA obtained in a representative ChIP experiment. The red dots indicate the probes enriched in Arx-immunoprecipitates
compared to total input DNA. B) Examples of the enrichment profiles of Arx-bound promoter regions visualized by DNA analytics software. The 3
lines represent data obtained from 3 independent ChIP-chip experiments and show the reproducibility between the 3 replicates. C) The resulting
weighted matrix discovered through the MDModule analysis (top) appears to be similar to the motif identified by Berger et al. [27] (bottom). D)
Frequency distribution of scores. The TAATTA motif identified by MDModule was significantly more present in ChIP-enriched sequences (red curve)
by comparison to negative control sequences (blue curve).
doi:10.1371/journal.pone.0025181.g002
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regulation of several important signaling pathways including G-
protein coupled-receptor, adenylate cyclase activity or neuroactive
ligand-receptor interaction (Figure 5B). Interestingly, several genes
identified in N2a-transfected cells and embryonic brain were
associated with axonal guidance (Figure 5C–D) and long-term
depression and/or long-term potentiation, suggesting a possible
function of Arx in synaptic plasticity (Figure 5E). We also
examined in more detail Arx targets associated with neuronal
function. As shown in Table 1, a certain number of them have
been associated with dyskinesia and neurological disorders
including phenotypes observed in ARX-mutated patients.
Using publicly available in situ hybridization data in mouse
(GenePaint, [29]), we next investigated the expression of some Arx
candidate target genes (Figure S1). In the developing cortex, Arx
has been shown to be expressed in progenitors of the dorsal
ventricular and subventricular zones as well as in tangentially
migrating interneurons coming from the ganglionic eminences but
not in radially migrating cells. On the contrary, in the basal
telencephalon, Arx is strongly expressed in differentiated neurons
but not in proliferating cells of the lateral and medial ganglionic
eminences [15–17]. As shown in Figure S1, several ChIP-positive
genes are expressed in the developing telencephalon at E14.5,
either in the cortical ventricular zone, or in regions containing
migrating and/or differentiating interneurons. For example, at
E14.5, Epha3, Sema3c, Cxcr7 and Snrpn appear to be expressed in
cortical migrating neurons, whereas Bhlhb5 and Gabrb3 seem to be
restricted to differentiating neurons in the cortical plate. Genes
Figure 3. ChIP-chip results obtained from mouse embryonic brain. A) Graph representing log2 probe intensities of Arx-immunoprecipitated
DNA (IP) and input DNA obtained in a representative ChIP experiment. The red dots indicate the probes enriched in Arx-immunoprecipitates
compared to total input DNA. B) Example of the enrichment profiles of Arx-bound promoter regions visualized by DNA analytics. The 3 lines
represent data obtained from 3 independent ChIP-chip experiments and show the reproducibility between the 3 replicates. Contrarily to N2a cells, in
which several continuous probes were often found enriched, only one or two probes were found enriched per gene. C) Venn diagram illustrating the
overlap (black) between Arx-immunoprecipitated genes in transfected N2a cells (blue) and mouse embryonic brain (red), and the number of genes
with at least 75% match to Arx-binding motif.
doi:10.1371/journal.pone.0025181.g003
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PLoS ONE | www.plosone.org 5 September 2011 | Volume 6 | Issue 9 | e25181Figure 4. Confirmation of Arx binding to candidate promoter regions. A) Arx-immunoprecipitated DNA was compared to input DNA by
ChIP/QFM-PCR to determine ChIP enrichment of 21 putative target genes. No enrichment occurred for the Vapb promoter which was consistently
negative in all ChIP experiments. Bar heights represent log10 enrichment of the signal obtained for Arx-immunoprecipitated DNA versus input DNA
for each promoter using site-specific primers. The arrows above the bars indicate sequences in which the previously defined Arx-binding motif was
Identification of Arx Targets
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cortical neuronal progenitors. Finally, genes like Tle1, Hist1h4h,
Hist2h3c, Rpn1 and Nxf1 also localize to developing ganglionic
eminences suggesting a possible role in interneuron development
(Figure S1).
Several ChIP-positive genes also have a role in the development
of other tissues in which Arx has been shown to be important, such
as the pancreas (Arntl, Onecut1, Brd2, Cdx1, Creb3l1, Dusp19,
Pik3r3…) or skeletal muscle (Casq1, Musk, Myh8, Ank1, Meg3…).
Others have important function in testis development (Cstf2t, Fert2,
Phkg2, Pxt1, Alkbh2, Ankrd7…). Further investigations of the
functions of Arx-potential targets also suggest that Arx may play
a role in a number of other processes in which it had not been
previously implicated such as in heart and blood vessel
development, bone formation and osteoblast differentiation,
proliferation and differentiation of myeloid/mesenchymal cells,
stem cell maintenance, RNA processing, protein transport and
clathrin-mediated endocytosis (Tables S2 and S3). Taken together,
these results suggest that Arx may be involved in a wide range of
cellular pathways at the transcriptional level.
Gene expression analysis of Arx-overexpressing N2a cells
As binding does not necessarily imply regulation, we next
checked whether the putative targets identified by ChIP-chip were
differently regulated following Arx overexpression. We thus
compared gene expression between Arx-transfected N2a cells
and cells transfected by the corresponding empty vector. We did 8
different independent experiments on which qRT-PCR was first
performed to confirm the expression of Arx in samples transfected
with Arx (data not shown). Then, cRNAs were hybridized on
microarrays representing 39430 Entrez Gene RNAs (Agilent
Technologies). Following hierarchical centroid-linkage clustering,
differentially expressed genes were grouped according to similar
variation in gene expression patterns, resulting in the identification
of 7 different clusters that represent 2145 genes (Figure 6A).
Among them, 908 genes (43%) were up-regulated and 1237 (59%)
were down-regulated in Arx-expressing cells, confirming previous
observations indicating that Arx acts primarily as a transcriptional
repressor [20,21,30]. As a confirmation of these results, we noted
that several of the genes we identified in the 7 clusters such as
Lmo1, Lmo4, Etv1, Lonrf3, Il17rd, Pcdh17, Socs2, Ank3, Atp7a, Bmper,
Foxp1, Phlda1, Zfp503 and Vcan had previously been found
deregulated in the striatum of Arx knock-out mice [21,22].
To investigate whether identified genes belong to functional
categories which could provide further insight into the role of Arx,
we used GoMiner to look at GO categories containing at least 3
genes and having a P-value#0.05 by Fisher’s exact test. This
analysis revealed that genes involved in learning and/or memory
function or synaptic transmission were found to be down-regulated
following Arx ectopic expression (clusters 1–4 and 6), whereas
those involved in signal transduction or cell proliferation were up-
regulated (clusters 5 and 7) (Figure 6B).
We next compared the list of the 927 ChIP-positive sequences
obtained in transfected N2a cells (Figure 3C, Table S1) with the
genes identified in the 7 clusters. Among genes represented on
both the expression and promoter microarrays, we found that 95
of the 927 Arx-bound genes (<10.2%) displayed expression
changes when Arx was overexpressed in N2a cells. This
percentage increased to 10.7% (108 genes out of 1006) when we
included the 79 genes that were found only in ChIP experiments
from embryonic brains (Figure 7A, Table S4).
Gene expression analysis of Arx knock-out mice
To investigate whether binding of Arx to candidate targets have
detectable effects on gene expression in more physiological
conditions, we took advantage of two studies comparing gene
expression between basal telencephalon of E14.5 Arx knock-out
and wild type mice [21,22]. These authors respectively identified
38 [22] and 84 genes [21], which expression was deregulated in
Arx knock-out mice. However, as both studies focused on genes
having a Fold-Change superior to 2 and our aim is to validate
potential targets of Arx which display changes in gene expression
but not necessarily important ones, we used the GeneSpring
software from Agilent Technologies to reanalyze their data. We
identified 2537 genes with expression changes .1.1 fold (P-
value#0.05) between Arx-mutated brains and controls. Taking
into account the two lists of published genes [21,22] and these
data, we observed that out of the 369 Arx putative targets
identified from mouse embryonic brain, 61 genes (<16.5%)
showed significantly changes in gene expression in Arx-mutant
brains. This percentage changed to 15.8% (159 genes out of 1006)
when we included the 637 genes that were found only in ChIP
experiments from Arx-transfected N2a cells (Figure 7B, Table S4).
Arx was previously described to act as both a transcriptional
repressor and transcriptional activator [20,21,30]. We thus looked
at whether Arx regulates genes in the same way in transfected N2a
cells and mutant brain. We noticed that the majority (67/108) of
Arx-bound genes that showed gene expression changes in
transfected cells were down-regulated (Figure 7A). On the
opposite, the majority (115/159) of Arx-bound genes that showed
gene expression changes in Arx knock-out mice was up-regulated
(Figure 7B). This result is consistent with previous studies
suggesting that Arx acts primarily as a transcriptional repressor
[20,21,30]. Interestingly, when looking at the 24 ChIP-positive
genes that show gene expression changes in both Arx-overex-
pressing cells and Arx knock-out mice (Figure 7C), we noticed that
9 genes (Table S4) showed the same type of regulation when Arx
was overexpressed or down-regulated (as for example Phlda1)
whereas 15 genes (Table S4) showed opposite behavior (as for
example Kcna5), suggesting that depending of the biological
context or the molecular environment, Arx may activate or
repress the same genes. We also noticed that there was no
correlation between the presence of the previously identified Arx-
binding site and the deregulation of these genes (data not shown),
suggesting once again that the TAATTA motif does not
necessarily mean regulation and that Arx may bind to other
DNA motifs. Taken together, our results demonstrate that a
substantial proportion of the direct targets of Arx identified by
ChIP-chip show gene expression changes following Arx overex-
pression or knock-down.
Discussion
ARX loss-of-function mutations in mouse and human have been
shown to affect several parts of the brain including the cortex,
thalamus, hippocampus, striatum and olfactory bulb [14,31,32].
found. B) Confirmation of Arx binding to 5 different promoter sequences identified by ChIP using a luciferase reporter gene assay. Firefly luciferase
data were normalized to Renilla luciferase expression and data are presented as the percentage of transcriptional activity compared to the vector
control. Arx regulation was confirmed for Lmo1, Lmo3, Sh3tc2, Calb2 and Cdh2 promoter regions as transcriptional activity was repressed in the
presence of Arx by comparison to the control transfection, whereas it had no effect on the plasmid alone pGL4.23. Error bars indicate SEM.
doi:10.1371/journal.pone.0025181.g004
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PLoS ONE | www.plosone.org 7 September 2011 | Volume 6 | Issue 9 | e25181Figure 5. Functional annotations of Arx targets. A) Significantly enriched biological functions obtained from the data in transfected N2a cells
(left) or embryonic brain (right) confirm already known functions of Arx in the regulation of gene expression, cellular growth and proliferation and
emphasizes its important role in the development of neurological and psychological disorders. The indicated P-value was calculated by Fisher’s exact
test. B) Significantly enriched canonical pathways associated with Arx targets. The top table indicates enriched genes from transfected N2a cells and
the bottom one indicates results from embryonic brain. The indicated P-value was calculated by Fisher’s exact test. Ratios correspond to the number
of ChIP-positive genes compared to the genes present on the array for each canonical pathway. C) and D) Examples of ChIP-positive genes (indicated
in grey) playing a role in the Axonal Guidance canonical pathway (image generated by the IPA program). E) Example of ChIP-positive genes (indicated
in grey) playing a role in synaptic transmission (image generated by the IPA program).
doi:10.1371/journal.pone.0025181.g005
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and tangential migration and interneuron subpopulation differen-
tiation [6,14,18]. Given the different roles Arx has been suggested
to play in brain development, it would be now interesting to
uncover the cellular pathways controlling these processes by
identifying the downstream targets of Arx in the central nervous
system. Therefore, in this work, we combined ChIP method to
identify Arx-bound promoters with studies of gene expression
changes following Arx overexpression or knock-down.
In total, we identified 1006 putative Arx-bound genes, several of
them involved in the patterning of the central nervous system,
axonal guidance, neurodevelopment, neurotransmission and
neurite outgrowth. Interestingly, we also suggest new possible
functions for Arx, as for example in osteoblast differentiation or
mesenchymal cell proliferation and differentiation. Although these
functions may be surprising as first glance, they may be related to
the expression of Arx in the neuroepithelium [15–17] and the
recent finding that mesenchymal stem cells are generated early in
development from the neuroepithelium [33]. As a validation of our
results, we identified in our ChIP-chip experiments Lmo1 and Ebf3
which had previously been described as direct targets of Arx [21].
In addition, the use of a different Arx antibody (anti-Arx-HD)
which identified a large number of overlapping targets in ChIP
experiments (data not shown), provides an independent level of
confirmation of our results.
Comparison between ChIP experiments performed in trans-
fected N2a cells and mouse embryonic brain revealed a large
degree of overlaping identified targets. In particular, we observed
that most of the genes identified only in embryonic brain were also
enriched in transfected cells, although the enrichment was below
our threshold of selection (see P-values in Table S1). For the vast
majority of the genes that we tested by ChIP-PCR, we were able to
validate Arx promoter binding not only in transfected N2a cells
but also using mouse embryonic brains immunoprecipitates
(Figure 4A). Similarly, we confirmed Arx fixation to Zic3, and
yet this gene was below our threshold of selection as it was positive
in only one experiment in transfected cells and one experiment in
embryonic brain. This observation suggests that some genes we
identified in only one or two replicates of ChIP experiments may
be true targets of Arx and that the number of genes we selected as
positive in all three replicates (1006 genes) may be slightly
underestimated.
We then showed that quantitative expression levels of putative
targets could be significantly altered by the ectopic expression of
Arx in N2a cells or its knock-down in ventral telencephalon. In
total, we found that approximately one quarter of Arx putative
targets were deregulated following increasing or decreasing Arx
levels in neuroblastoma cells or embryonic brain. However, this
number is probably underestimated as Arx is normally not
expressed in N2a cells and may thus lack binding partners and/or
cofactors necessary to regulate the expression of certain genes. For
example, we noticed that among the 159 ChIP-positive genes that
showed gene expression changes in mutant brain, 135 genes did
not show any mRNA change in Arx-transfected N2a cells. In
addition, Fulp and Colasante have focused on ventral telenceph-
alon for their gene expression experiments [21,22], thus probably
leaving out genes involved in neuroblast proliferation and/or
radial migration. Similarly, as we selected only one stage of
development in mouse in our ChIP experiments, it is likely that we
missed several genes involved in earlier steps such as brain
patterning or on the contrary later steps such as synaptogenesis
and connectivity. Some changes in gene expression may also be
too low to be detected in microarrays experiments. It is for
example the case of Gabrb3, Lmo3 or Cdh2 that show a change of
expression in qRT-PCR experiments following Arx expression in
N2a cells (data not shown) but not on microarrays.
In conclusion, this study presents the first global analysis of Arx
direct transcriptional targets. Identified genes are involved in a wide
range of cellular processes suggesting new and expanded roles for
this transcription factor. As detailed above, Arx directly regulates
genes required for cell-cycle control, tight-junction dynamics, cell
morphology, neuronal migration and differentiation as well as
Table 1. Examples of Arx-immunoprecipitated genes and their corresponding functional category.
Function Molecules
schizophrenia AHI1, ALK, BRD1, FXYD6, GNAS, GRIA1, HTR7, LGI1, NAALAD2, NDE1, NTNG1, PPP3CC, SIGMAR1, SLC1A1, TH, TPH1, NRXN1, BRD1, CCDC60
mental retardation ATRX, GRIA3, PRSS12, TSPAN7, AHI1, TIMM8A, BBS12, ATRNL1, ZDHHC9, NRXN1, L1CAM, RAB39B, RASGEF1B, ALG2, NFIB, SNRPN
epilepsy GABRB3, GABRE, GAD2, GRIA1, GRIA3, LGI1, OTX1, SLC12A5, LGI1, OTX1, KCNAB1, KCNJ14, RAB39B
autism AHI1, ATRX, BTD, FGFGR2, GRIA3, L1CAM, NRXN1, PRSS12, PTEN, RAB39B, NTNG1, NRXN1
dyskinesia ACTN2, AEBP1, ARMCX2, ATP5J, CAPNS1, CASQ1, CCKBR, CDH2, CHN1, CHRM4, CRB1, CREB3L1, CYP26B1, EGR1, EPHX2, FOSB, GABRB3,
GABRE, GAD2, GNAO1, GNAT2, GPD1, GRIA1, GRIA3, HBP1, HSPA5, IDO1, IGF1, KCNA5, KCNAB1, MEIS2, MYT1L, NDRG1, NKX2-1, NR4A1, OXR1,
PDE10A, PDE6B, PDLIM1, PFN2, PPARG, PPARGC1A, PPP1R3A, PRKCB, PRL, RAB5A, SCOC, SDC4, SLC1A1, SLC6A2, SLIT2, SPOCK3, SRPX,
TCERG1, TH, TPD52, TSC22D3, TUBA1A, UGCG
depressive disorder ACE, ATG5, BTD, CCKBR, CHGA, CHRM4, CHRNG, CTR9, GABRB3, GABRE, GPR50, GRIA1, GRIA3, HTR7, IGF1, LMNB2, MDFI, PDE10A, PDE1A,
PPARG, SIGMAR1, SLC1A1, SLC6A2, TACR2, TOB1, TPH1, WFS1
synaptic plasticity and
synaptogenesis
GHRH, MUSK, PCDHB5, PCDHB10, DNM2, P2RX1, GLRA3, PRSS12, GABRB3, GRIA3, DOC2B, CHRNG, CHRM4, GRM1, PSD3, SV2A, CPEB1, LIN7C,
L1CAM, GRIA1, GABRE, TH, NRXN1, GAD2, DGKZ, LRRTM2, ACCN5, ACTN2, ACTR3, ACVRL1, ADORA3, ARHGAP5, CACNA2D1, CADM3, CAV1,
CCKBR, CDH2, CNTN1, CTNNA2, CYBB, NRXN1, LGI1, CACNG4, CTNNA2, RASGEF1B, CDH2, JPH4, RTN4R, SLC1A1, EPHB1, PPP2R1A, GNAI3,
GNAO1, GNAI1, IGF1, GNAS, GRIA3, GRM1, EGR1
neuronal differentiation TH, L1CAM, PTEN, EPHB1, OTP, MYCBP2, LINGO1, SRPX, CRB1, POU4F3, POU4F2, LHX5, PHOX2A, EFNB3, FOXA1, NTNG1, SMAD4, NR4A2,
RTN4R, SOD1, FGF20, SLIT2, GNAT2, FOXN4, CTNNA2, SALL3, SEMA6A, NRL
axonogenesis SEMA6A, EFNB3, POU4F3, NTNG1, RTN4R, NR4A2, POU4F2, L1CAM, EPHB1, SLIT2, CTNNA2, MYCBP2, CHD2, SHROOM3, EDNRA, CHN1
axonal guidance GNAI3, EFNB3, GNAI1, NTNG1, L1CAM, SLIT2, EPHB1, EPHA3, SEMA6A, SEMA3G, PPP3CC, SEMA3C, UNC5D
size and morphology of
the brain
HSF2, L1CAM, PTEN, IGF1, NDE1, PTEN, WASF1, CTNNA2, AHI1, ASPM, ARHGAP5, CDH2, TUBA1A, EOMES
doi:10.1371/journal.pone.0025181.t001
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PLoS ONE | www.plosone.org 10 September 2011 | Volume 6 | Issue 9 | e25181synaptic plasticity modulation, neurotransmission and axonal
guidance. Among the different targets we identified, a number of
genes are known to be important for brain development and some
have already been linked to human disorders. But in addition, we
identified newgeneswhichmaybegoodcandidatestotestinhuman
neurological and psychological diseases. Further studies to under-
stand their function and their relation to Arx will certainly bring
new insight into the understanding of the pathophysiology of
intellectual disability and epilepsy.
Materials and Methods
Cell culture and reagents
Neuro2a (N2a) mouse neuroblastoma cells (IFO50081) were
obtained from the Japanese Collection of Research Bioresources
(http://cellbank.nibio.go.jp/). These cells were grown in Dulbec-
co’s modified Eagle medium (DMEM) high glucose (PAA) which
was supplemented with 10% fetal bovine serum gold (PAA), 2 mM
L-glutamine (Lonza), 0.1 mM non essential amino-acids (Gibco)
and 2 mM penicillin/streptomycin (PAA). Cells were grown at
37uC with 5% CO2 and transfected with an expression vector
expressing Arx using Lipofectamine 2000 according to the
guidelines of the manufacturer (Invitrogen).
Chromatin immunoprecipitation
Two days after transfection, 10
6 N2a cells were fixed in 1%
formaldehyde at room temperature for 10 min, followed by the
addition of 125 mM glycine to stop the cross-linking reaction.
Cells were then resuspended in ice-cold lysis buffer (50 mM Tris-
HCl [pH 8.0], 10 mM EDTA, 1% SDS and Protease Inhibitor
Cocktail (Roche)). To ensure that DNA fragments ranged from
300 to 600 base pairs (bp), samples were sonicated using a
Transsonic T460/H (Elma) in an ice bath with 34 rounds of 30-s
sonication pulses and an incubation of 1 min between each round.
Samples were then centrifuged at 17 900 g at 4uC for 15 min to
remove cell debris. Twenty microliters of the sonicated solution
were stored at 4uC as Total Input, while the rest was incubated
with 1 mg of either ARX C-terminal antibody (sc-48843, Santa
Cruz) or anti-Arx-HD [15] or Pol II N-terminal antibody (sc-899,
Santa Cruz) rotating overnight at 4uC. Immune complexes were
captured the following day by addition of 40 ml of Dynabeads
Protein G (Invitrogen) blocked with salmon sperm DNA (Applied
Figure 6. Gene expression analysis following Arx expression in N2a cells. A) Heat map representing hierarchical clustering of the ratio ‘‘Arx-
transfected cells/control-transfected cells’’ in 8 different replicates. Each row represents a gene and each column, a sample. Levels are color-coded
with red, green and black, corresponding to an increase, decrease or no change in gene expression, respectively. Seven clusters of genes with the
same regulation were identified. B) Functional annotation of genes in the seven clusters using the GoMiner program.
doi:10.1371/journal.pone.0025181.g006
Figure 7. Gene expression changes of Arx candidate targets. A) Venn diagram illustrating the number of ChIP-positive genes that were found
to show expression changes in Arx-overexpressing cells. The Pie diagram shows the number of ChIP-positive genes that are down-regulated
(indicated in green) or up-regulated (indicated in red). B) Venn diagram illustrating the number of ChIP-positive genes that were found to show
expression changes in Arx knock-out ventral forebrain. The Pie diagram shows the number of ChIP-positive genes that are down-regulated (indicated
in green) or up-regulated (indicated in red). C) Venn diagram illustrating the number of ChIP-positive genes that show gene expression changes in
both Arx-overexpressing cells and Arx knock-out mice.
doi:10.1371/journal.pone.0025181.g007
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with gradient stringent buffers, protein-DNA complexes were
eluted by a solution of 1% SDS and 0.1 M NaHCO3 for 30 min at
room temperature. The eluted solution, as well as the stored Input,
was incubated with 0.2 M NaCl, 2 h at 65uC to reverse cross-link.
Immunoprecipitated DNA and Input DNA were then isolated via
phenol-chloroform extraction followed by ethanol precipitation.
Concentration and purity of DNA were assessed using a
NanoDrop spectrophotometer.
Chromatin immunoprecipitation on embryonic brains from
wild-type mice was performed following a similar protocol. All
animal procedures were performed in accordance with French and
international guidelines and were approved by the French review
board ministe `re (authorization ID: 29AUTEX005). Briefly, adult
pregnant female mice were killed by cervical dislocation and
brains were extracted from day 15.5 (E15.5) embryos in cold PBS.
Following brain isolation, the whole forebrain including ventral
telencephalon, thalamus, cerebral cortex and olfactory bulbs were
frozen in liquid nitrogen and kept at 280uC for further
experiments. For each experiment, tissue was pooled from 3
embryos. Tissue disaggregation and homogenization were per-
formed in liquid nitrogen using a pestle and a mortar. Samples
were then transferred into a 15 ml Falcon tube and fixed in a
solution containing PBS, 1% formaldehyde and Protease Inhibitor
Cocktail (Roche). Following steps were identical to those described
above.
DNA amplification, labelling and hybridization on
microarrays
Equivalent amounts of immunoprecipitated chromatin and total
input DNA were amplified in parallel, using a random primer
method with the GenomePlex Complete Whole Genome
Amplification Kit (15 cycles), according to the manufacturer’s
instructions (Sigma).
Two micrograms of amplified immunoprecipitated and input
DNA samples were labelled with Alexa Fluor 647 or Alexa Fluor
555 respectively, by use of random primers provided in the
BioPrime Plus Array CGH Indirect Genomic Labelling System
(Invitrogen). A total of 5 mg of labelled DNA was then hybridised
to mouse promoter ChIP-chip microarrays set (G4490A, Agilent
Technologies) for 40 h at 65uC. After 4 successive washes,
hybridization images were obtained using an Agilent DNA
microarray scanner (G2505B) and intensity data were extracted
using Feature Extraction software (FE v9.5.1) (Agilent Technol-
ogies). Results were visualised using the DNA Analytics software
4.0.85 (Agilent Technologies).
ChIP-chip data analysis and positive probes selection
Intensity data on each array were normalized with the Lowess
(Locally weighted scatterplot smoothing) method [34–36], pooled
and represented on a graph. To identify regions of significant Arx
association, the enrichment of each probe on the array was
calculated as the log2-ratio of the intensities of Arx-immunopre-
cipitated DNA (y-axis) to control input chromatin (x-axis). One
first important assumption is that points corresponding to non
positive probes are distributed symmetrically around the axis x=y.
A threshold spline curve was then defined by considering only the
probes below this axis. Reporting this curve above the axis allowed
discrimination between positive and negative probes. For each
probe, a P-Value was obtained using a normalised distance
between it and the axis x=y. All ChIP data are MIAME
compliant and raw data have been deposited into NCBI Gene
Expression Omnibus (GEO), and can be accessed with accession
number GSE29985.
Validation of target genes by PCR or QFM-PCR on ChIP-
extracted DNA
Before DNA was applied to microarrays, the efficiency of
chromatin immunoprecipitation was assessed by measuring the
enrichment of Ebf3, Lmo1 and Shox2 promoters in Arx-immuno-
precipitated material. Primers targeting these regions as well as the
Gapdh control were the same as those published by Fulp et al. [21].
Real-time PCR was then performed using the Quantitect SYBR
Green PCR Master mix (Qiagen) on a 7300 Real-Time PCR
System (Applied Biosystems). The enrichment of the 3 targets was
expressed as ‘‘% of Input’’ and was calculated following the SA
Biosciences analysis instructions (www.sabiosciences.com/manu-
als/chipqpcranalysis.xls). Briefly, normalised Ct values for each
sample were calculated by subtracting the Ct value obtained using
input DNA from the Ct value obtained using Arx-immunopre-
cipitated DNA and the dilution factor [Ct(IP)] – [Ct(input) –
Dilution factor]. Then, ‘‘% Input’’ was calculated using the
formula: (2
2DCt)6100.
Semi-quantitative fluorescent multiplex (QFM)-PCR was per-
formed to confirm Arx fixation onto selected putative targets. The
assay is based on multiplex PCR of short fragments and on the
comparison of fluorescent patterns obtained from Arx-immuno-
precipitated DNA and input DNA. Primers targeting Arx-bound
regions were designed using PrimerQuest and Oligo Analyzer
(IDT Integrated DNA Technologies, http://eu.idtdna.com/
Home/Home.aspx) and are listed in Table S5. The optimal
PCR conditions including primer concentration, annealing
temperature, and number of amplification cycles were adjusted
to ensure that each PCR was still in the exponential phase of
amplification. PCR was performed with 100 ng of DNA, using the
Multiplex PCR master mix 26 kit (Qiagen). Amplified DNA
fragments were separated on an ABI PRISM 310 sequencer
(Applied Biosystems) at 60uC using POP4 polymer and data were
analysed by superimposing fluorescent profiles of immunoprecip-
itated DNA and input DNA using the GeneMapper v3.4 software
(Applied Biosystems).
Identification of motifs associated with Arx-binding
Motif discovery was performed on 450 bp masked sequences
centered on the 500 best positive probes. We used the MDmodule
of the MotifRegressor program [25], which allowed us to discover
motifs of different sizes. In order to eliminate redundancies
between all the identified motifs and compare them with Jaspar
[37] and Transfac [38] databases, the MotifsComparator program
[26] was used. Similar motifs were gathered leading to a consensus
motif, which was generated with the WebLogo tool (http://
weblogo.berkeley.edu/). A statistical significance for these motifs
was performed using a Chi-square homogeneity test and
comparing its score distribution in a set of positive probes and a
set of non-positive probes.
Similarly, 400 bp-sequences flanking all positive probes were
scanned using EMBOSS Profit (http://bioweb2.pasteur.fr/docs/
EMBOSS/profit.html) for motifs corresponding to Prophecy-
generated frequency matrixes of our discovered motif and the one
defined by the study of Berger et al. [27].
Luciferase reporter assays
N2a cells were transfected 24 h after plating in 24-well dishes
with 500 ng of putative promoters cloned into the luciferase
reporter plasmid pGL4.23 expressing the firefly luciferase (Pro-
mega), 200 ng of Arx-expressing vector or vector alone and
100 ng of pGL4.74 vector expressing the Renilla luciferase
(Promega) using Lipofectamine 2000. Forty-eight hours after
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luciferase activity on a Fluoroskan Ascent FL microplate
luminometer (Thermo Scientific) were performed using the
Dual-Glo Luciferase Assay System (Promega) according to the
manufacturer’s instructions. Transfections were performed in
triplicate. The firefly luciferase activity was normalized according
to the corresponding Renilla luciferase activity to correct
transfection efficiency and luciferase activity was reported as a
mean relative to the results obtained with the expression vector
alone.
Functional annotations
Statistical analysis of the enrichment of Gene Ontology (GO)
categories was performed using the Database for Annotation,
Visualization and Integrated Discovery (DAVID) (http://david.
abcc.ncifcrf.gov/) [39] and the Ingenuity Pathway Analysis
(Ingenuity Systems) software (http://www.ingenuity.com/). Enrich-
ment was determined in reference to the genes on the microarray.
Gene expression analysis
Two days after transfection, RNA from N2a cells (1610
6) was
isolated using the Total RNA Isolation Nucleospin RNA II kit
following the manufacturer’s instructions (Macherey-Nagel). After
measuring RNA concentration using a Nanodrop ND-1000
spectrophotometer, RNA integrity was assessed with the Agilent
2100 BioAnalyzer (Agilent Technologies) by measuring the RIN.
Samples were loaded on the RNA 6000 Nano chip. In addition,
quantitative real-time one-step RT-PCR was performed to
confirm the enrichment of Arx in samples transfected with Arx
compared to samples transfected with plasmid control.
RNA (100 ng) was then labelled using the Low Input Quick
Amp Labelling kit (Agilent Technologies). RNA spike-in controls
were used to adjust possible dye effects. Briefly, 2 mg of total RNA
were mixed with spikes-in and converted to cDNA using reverse
transcriptase and oligo-dT primers in which T7 promoter
sequences were added. T7 RNA polymerase was used for the
synthesis and labelling of cRNA with either Cy3 dye or Cy5 dye.
The fluorescent labelled cRNA probes were purified using the
RNeasy Mini kit (Qiagen). An equal amount (825 ng) of Cy3 and
Cy5 labeled cRNA probes were hybridized on Mouse Gene
Expression 4644 K V2 microarray (Agilent Technologies).
Hybridization was performed for 17 h, rotating at 10 rpm at
65uC. Then, samples were washed and dried according to the
manufacturer’s instructions. Hybridization images were obtained
using an Agilent DNA microarray scanner and intensity data was
extracted using Feature Extraction software (Agilent Technolo-
gies). Transcriptomic data are MIAME compliant and raw data
have been deposited into GEO and can be accessed with accession
number GSE30190.
To characterize the differences in the profile of gene expression
between control and cells transfected by Arx, the Lowess (Locally
weighted scatterplot smoothing) method was used to normalize
data expression [34–36]. Then, the matrix was filtered to eliminate
low intensity probes and the ratio ‘‘Arx intensity/Control plasmid
intensity’’ was calculated for each probe. Genes with differential
expression were classified using the hierarchical clustering
program Cluster [40] and the expression level of each gene was
log-transformed. The clustering method used here was a centroid
linkage with the uncentered correlation coefficient as similarity
metric. Results were displayed using the Java TreeView program
(http://jtreeview.sourceforge.net/) [41]. Information on probes
was retrieved with the MADGene resource [42] and clusters of
genes with the same regulation were then functionally annotated
using GoMiner (http://discover.nci.nih.gov/gominer/index.jsp)
[43].
Gene expression analysis using Genespring software
To analyze the microarray data generated by Fulp and
Colasante from E14.5 Arx-mutant brains [21,22], we downloaded
their datasets (GSE12609 and GSE12956) from Gene Expression
Omnibus (GEO) and reanalyzed them using GeneSpring (Agilent
technologies) for the statistical analysis. The method of Benjamini
and Hochberg was applied for the multiple corrections with a P-
value cut-off of 0.05 [44] and a fold change $1.1 or #21.1 to
obtain genes with a statistically significant change of expression.
Supporting Information
Figure S1 Example of the expression of ChIP-positive genes
representative of some of the enriched biological categories in
E14.5 mouse brain. Images were obtained from the public
database GenePaint. The majority of genes are expressed in the
developing cortex and/or ganglionic eminences, consistent with a
positive or negative regulation by Arx. Ctx: cortex, VZ: ventricular
zone, CP: cortical plate, Hip: hippocampus, vTh: ventral
thalamus, GE: ganglionic eminences, OB: olfactory bulb.
(TIF)
Table S1 ChIP-positive gene promoters identified only in N2a-
transfected cells (sheet 2), only in embryonic brain (sheet 3) or in both
(sheet 1). The indicated P-value for each gene corresponds to the
geometrical mean of the best probe obtained from the 3 replicate
experiments. Genes are listed in decreasing P-value rank order.
(XLS)
Table S2 Functional gene ontology categories enriched in ChIP-
positive genes from N2a cells. The number and percentage of
genes in each GO category are presented. The indicated P-value
corresponds to modified Fisher Exact P-Value for gene-enrich-
ment analysis (EASE score).
(XLS)
Table S3 Functional gene ontology categories enriched in ChIP-
positive genes from mouse embryonic brain. The number and
percentage of genes in each GO category are presented. The
indicated P-value corresponds to modified Fisher Exact P-Value
for gene-enrichment analysis (EASE score).
(XLS)
Table S4 List of ChIP-positive genes showing changes of
expression following Arx overexpression in N2a cells and/or in
Arx knock-out mice.
(XLS)
Table S5 Site-specific primers used in ChIP/QFM-PCR for the
validation of Arx-bound promoter sequences.
(DOC)
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